Brief: Aldeyra Therapeutics Announces Positive Results From Phase 2 Clinical Trial In Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline On Next-Generation Molecules
28/10/2025 11:04
Oct 28 (Reuters) - Aldeyra Therapeutics Inc ALDX.O: ALDEYRA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM PHASE 2 CLINICAL TRIAL IN ALCOHOL-ASSOCIATED HEPATITIS, FOCUSES RASP PRODUCT CANDIDATE PIPELINE ON NEXT-GENERATION MOLECULES ALDEYRA THERAPEUTICS INC - ADX-629 SHOWS SIGNIFICANT IMPROVEMENT IN LIVER FUNCTION ALDEYRA THERAPEUTICS INC - CASH RUNWAY EXTENDED INTO SECOND HALF OF 2027 Source text: ID:nBw9r6syna Further company coverage: ALDX.O
Recent news on Aldeyra Therapeutics
See all newsBrief: Aldeyra Therapeutics Announces Intent To Submit Formal Dispute Resolution Request For Reproxalap To Treat Dry Eye Disease
Aldeyra Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aldeyra Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Aldeyra Therapeutics Pays Off $15 Million Outstanding Borrowings, Terminates Hercules Credit Facility - SEC Filing
U.S. STOCKS ON THE MOVE -Steel Dynamics, Aldeyra, Cencora